Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline
Aktis Oncology filed for a US IPO on December 19, 2025, seeking approximately $100 million to end a biotech IPO drought.
The company has a partnership with Eli Lilly worth up to $1.1 billion, including $60 million upfront, announced in May 2024, for radiopharmaceutical development.
Lead candidate AKY-1189 is in Phase Ib NECTINIUM-2 trial for Nectin-4 expressing solid tumors (e.g., lung, colorectal, cervical); initial data expected Q1 2027.
AKY-2519 is preparing an IND for B7-H3 expressing solid tumors.
Aktis has raised $346 million since 2020, including $175 million Series B in 2024; net loss $48.6 million in nine months ended Sep 30, 2025.
Will list on Nasdaq under ticker AKTS.